Teva Pharmaceutical Industries (TEVA) EBIT Growth (3y) (2012 - 2026)
Teva Pharmaceutical Industries (TEVA) EBIT Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | -59.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.31% |
| Mar 31, 2026 | 273.62% |
| Dec 31, 2025 | 32.37% |
| Sep 30, 2025 | 27.65% |
| Jun 30, 2025 | 35.19% |
| Mar 31, 2025 | 39.73% |
| Dec 31, 2024 | -33.36% |
| Sep 30, 2024 | -27.69% |
| Jun 30, 2024 | -26.17% |
| Mar 31, 2024 | -35.76% |
| Dec 31, 2023 | 23.03% |
| Sep 30, 2023 | 27.63% |
| Jun 30, 2023 | -79.47% |
| Mar 31, 2023 | -27.41% |
| Dec 31, 2022 | -102.89% |
| Sep 30, 2022 | 93.41% |
| Jun 30, 2022 | -14.51% |
| Mar 31, 2022 | -94.17% |
| Dec 31, 2021 | 26.51% |
| Sep 30, 2021 | 238.94% |